Mebias Discovery
Phase 1Our proprietary membrane protein-NMR drug discovery platform identifies molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.
Founded
2016
Focus
Small Molecules
About
Our proprietary membrane protein-NMR drug discovery platform identifies molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.
Company Info
TypePrivate
Founded2016
LocationPhiladelphia, United States
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile